帕金森病
生物
RNA剪接
选择性拼接
实时聚合酶链反应
TAF1
分子生物学
细胞生物学
医学
核糖核酸
信使核糖核酸
基因表达
基因
内科学
疾病
遗传学
发起人
作者
Jamal Al Ali,Christine A. Vaine,Shivangi Shah,Lindsey N. Campion,Ahmad Hakoum,Melanie L. Supnet,Patrick Acuña,Gabrielle Aldykiewicz,Trisha Multhaupt‐Buell,Niecy G.M. Ganza,J. Benedict B. Lagarde,Jan K. De Guzman,Criscely L. Go,Benjamin Currall,Bianca A. Trombetta,Pia Kivisäkk Webb,Michael E. Talkowski,Steven E. Arnold,Pike-See Cheah,Naoto Ito
摘要
ABSTRACT Background X‐linked dystonia‐parkinsonism is a rare neurological disease endemic to the Philippines. Dystonic symptoms appear in males at the mean age of 40 years and progress to parkinsonism with degenerative pathology in the striatum. A retrotransposon inserted in intron 32 of the TAF1 gene leads to alternative splicing in the region and a reduction of the full‐length mRNA transcript. Objectives The objective of this study was to discover cell‐based and biofluid‐based biomarkers for X‐linked dystonia‐parkinsonism. Methods RNA from patient‐derived neural progenitor cells and their secreted extracellular vesicles were used to screen for dysregulation of TAF1 expression. Droplet‐digital polymerase chain reaction was used to quantify the expression of TAF1 mRNA fragments 5′ and 3′ to the retrotransposon insertion and the disease‐specific splice variant TAF1‐32i in whole‐blood RNA. Plasma levels of neurofilament light chain were measured using single‐molecule array. Results In neural progenitor cells and their extracellular vesicles, we confirmed that the TAF1 ‐3′/5′ ratio was lower in patient samples, whereas TAF1 ‐32i expression is higher relative to controls. In whole‐blood RNA, both TAF1‐3′/5′ ratio and TAF1‐32i expression can differentiate patient (n = 44) from control samples (n = 18) with high accuracy. Neurofilament light chain plasma levels were significantly elevated in patients (n = 43) compared with both carriers (n = 16) and controls (n = 21), with area under the curve of 0.79. Conclusions TAF1 dysregulation in blood serves as a disease‐specific biomarker that could be used as a readout for monitoring therapies targeting TAF1 splicing. Neurofilament light chain could be used in monitoring neurodegeneration and disease progression in patients. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
科研通智能强力驱动
Strongly Powered by AbleSci AI